PMID- 26884326
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20181202
IS  - 1179-1942 (Electronic)
IS  - 0114-5916 (Linking)
VI  - 39
IP  - 6
DP  - 2016 Jun
TI  - The Safety of Prochlorperazine in Children: A Systematic Review and 
      Meta-Analysis.
PG  - 509-16
LID - 10.1007/s40264-016-0398-9 [doi]
AB  - INTRODUCTION: Prochlorperazine is recommended for adults with breakthrough or 
      refractory chemotherapy-induced nausea and vomiting (CINV). The objective of this 
      review was to describe its safety in children when given for any indication to 
      help define its role for CINV control in children. METHODS: Electronic searches 
      of MEDLINE, EMBASE, PsycINFO, and the Cochrane Central Register of Controlled 
      Trials were performed as of 9 March 2015. All studies in English reporting 
      adverse effects (AEs) associated with prochlorperazine in children (</=18 years) 
      were included. AEs were synthesized for prospective studies. RESULTS: Forty-nine 
      (15 prospective) studies evaluating the use of prochlorperazine in 758 children 
      were included. The most commonly reported AEs in prospective studies of 
      prochlorperazine in children were sedation (multiple-dose studies: 10 %, 95 % CI 
      5-21) and extrapyramidal symptoms (EPS) (single-dose studies: 9 %, 95 % CI 3-29; 
      multiple-dose studies: 4 %, 95 % CI 1-11). Serious AEs (seizure, neuroleptic 
      malignant syndrome, autonomic collapse, tardive dyskinesia) were rarely 
      associated with prochlorperazine use in children. Five fatalities were reported 
      in children receiving prochlorperazine. LIMITATIONS: The limitations of this 
      systematic review and meta-analysis were that the AEs reported in the included 
      studies were heterogeneous, the prospective use of systematic clinical tools to 
      identify AEs was rare, and the risk of bias in most prospective studies was 
      moderate. CONCLUSIONS: The most common AEs reported with the pediatric use of 
      prochlorperazine are EPS and sedation. Fatalities, life-threatening, and 
      persistent AEs have also been reported.
FAU - Lau Moon Lin, Melissa
AU  - Lau Moon Lin M
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
FAU - Robinson, Paula D
AU  - Robinson PD
AD  - Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
FAU - Flank, Jacqueline
AU  - Flank J
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
AD  - Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada.
FAU - Sung, Lillian
AU  - Sung L
AD  - Division of Haematology/Oncology, Department of Paediatrics, The Hospital for 
      Sick Children, Toronto, ON, Canada.
AD  - Research Institute, The Hospital for Sick Children, 555 University Ave, Toronto, 
      ON, M5G 1X8, Canada.
FAU - Dupuis, L Lee
AU  - Dupuis LL
AD  - Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada. 
      lee.dupuis@sickkids.ca.
AD  - Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada. 
      lee.dupuis@sickkids.ca.
AD  - Research Institute, The Hospital for Sick Children, 555 University Ave, Toronto, 
      ON, M5G 1X8, Canada. lee.dupuis@sickkids.ca.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - New Zealand
TA  - Drug Saf
JT  - Drug safety
JID - 9002928
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - YHP6YLT61T (Prochlorperazine)
SB  - IM
MH  - Antiemetics/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Chemotherapy-Induced Febrile Neutropenia
MH  - Child
MH  - Child Health Services
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Nausea/chemically induced/*drug therapy
MH  - Prochlorperazine/adverse effects/*therapeutic use
MH  - Risk Assessment
MH  - Vomiting/chemically induced/*drug therapy
EDAT- 2016/02/18 06:00
MHDA- 2017/12/06 06:00
CRDT- 2016/02/18 06:00
PHST- 2016/02/18 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
AID - 10.1007/s40264-016-0398-9 [pii]
AID - 10.1007/s40264-016-0398-9 [doi]
PST - ppublish
SO  - Drug Saf. 2016 Jun;39(6):509-16. doi: 10.1007/s40264-016-0398-9.